According to a recent LinkedIn post from ETHOS DISCOVERY, the company is drawing attention to new research from its Ethos-PUSH study examining outcomes for dogs with benign splenic tumors. The post notes that in a cohort of 83 dogs undergoing splenectomy, only 4 reportedly experienced recurrent bleeding, and suggests that euthanasia may not be the only option for owners facing this diagnosis.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post highlights ETHOS DISCOVERY’s engagement in clinically focused veterinary research that could influence standards of care in companion animal oncology. For investors, this type of data-driven evidence may strengthen the company’s reputation with veterinarians, support future demand for related services or studies, and potentially enhance its positioning in the growing advanced veterinary care and pet health markets.